Nuvation Bio CCO granted 748,130 share stock option

Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, received a grant of stock options covering 748,130 shares on February 27, 2026.

Rhea-AI Filing Summary

Nuvation Bio Inc.'s Chief Commercial Officer, Colleen Sjogren, received a grant of stock options covering 748,130 shares on February 27, 2026. These options vest as to 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months, subject to her continuous service. Following this grant, she directly owned 84,000 shares of Class A common stock, which includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Grant/Award: 748,130 shares

Grant/Award 2 txns

Insider Sjogren Colleen

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	748,130	$0.00	$0.00
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 748,130 contracts (Direct); Class A Common Stock — 84,000 shares (Direct)

Footnotes (2)

1. F1. Includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.
2. F2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nuvation Bio (NUVB) disclose for Colleen Sjogren?

Nuvation Bio disclosed that Chief Commercial Officer Colleen Sjogren received a stock option grant covering 748,130 shares on February 27, 2026. The Form 4 records this as an acquisition through a grant or award rather than an open-market purchase or sale.

How many Nuvation Bio (NUVB) shares are covered by Colleen Sjogren’s new stock option?

The new stock option granted to Colleen Sjogren covers 748,130 shares of Nuvation Bio Class A common stock. This is reported as a derivative security labeled “Stock Option (Right to Buy)” with a grant, award, or other acquisition transaction code on February 27, 2026.

What is the vesting schedule for Colleen Sjogren’s Nuvation Bio (NUVB) stock option grant?

The stock option vests 25% on the one-year anniversary of February 27, 2026, then monthly over the following 36 months. Each vesting date requires continuous service by Colleen Sjogren, meaning she must remain employed or in service for the options to continue vesting.

How many Nuvation Bio (NUVB) common shares does Colleen Sjogren hold after this Form 4?

After the reported transactions, Colleen Sjogren directly beneficially owned 84,000 shares of Nuvation Bio Class A common stock. This total reflects her direct holdings as of the reporting date and is separate from the 748,130 shares underlying the newly granted stock option.

What does the footnote about 3,000 Nuvation Bio (NUVB) shares indicate?

A footnote states that 3,000 shares were acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan. These shares are included within Colleen Sjogren’s 84,000 directly held Class A common shares reported after the February 27, 2026 transactions.

Is Colleen Sjogren’s Nuvation Bio (NUVB) stock option grant reported as a buy or an award?

The stock option is reported as a grant or award acquisition, not an open-market buy. The Form 4 uses transaction code A for “Grant, award, or other acquisition,” and the transaction direction field classifies it as an acquire event for a derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 08:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sjogren Colleen

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock								84,000(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.91	02/27/2026		A		748,130		(2)	02/26/2036	Class A Common Stock	748,130	$0	748,130	D

Explanation of Responses:

1. Includes 3,000 shares acquired on November 19, 2025 under the 2021 Employee Stock Purchase Plan.

2. Option vests as to 25% on the one year anniversary of 2/27/2026, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.